TY - JOUR
T1 - Tetrahydroberberine blocks ATP-sensitive potassium channels in dopamine neurons acutely-dissociated from rat substantia nigra pars compacta
AU - Wu, Chen
AU - Yang, Kechun
AU - Liu, Qiang
AU - Wakui, Matoko
AU - Jin, Guo zhang
AU - Zhen, Xuechu
AU - Wu, Jie
N1 - Funding Information:
We thank Dr. Denis Lecavalier for his assistance to edit the manuscript. This work was supported by CHW Seed Fund (J.W.), and the part of work in this study was also supported by Chinese government grants (973-project: 2009CB52200 ; CNSF : 30825042 ; International Collaboration Grant ).
PY - 2010/12
Y1 - 2010/12
N2 - Tetrahydroberberine (THB) exhibits neuroprotective effects but its targets and underlying mechanisms are largely unknown. Emerging evidence indicates that ATP-sensitive potassium (KATP) channels in the substantia nigra pars compacta (SNc) promote Parkinson disease (PD) pathogenesis, thus blocking KATP channels may protect neurons against neuronal degeneration. In the present study, we tested a hypothesis that THB blocks KATP channels in dopaminergic (DA) neurons acutely dissociated from rat SNc. Using perforated patch-clamp recording in current-clamp mode, the functional KATP channels can be opened by persistent perfusion of rotenone, an inhibitor of complex I of the mitochondrial respiratory chain. Bath-application of THB reversibly blocks opened KATP channels in a concentration-dependent manner, which is comparable to a classical KATP channel blocker, Tol. Compared to THB analogs, l-stepholidine (l-SPD) or l-tetrahydropalmatine (l-THP), THB exhibits more profound blockade in KATP channels. In addition, exposure of THB alone to the recorded neuron increases action potential firing, and THB also restores rotenone-induced membrane hyperpolarization in the presence of dopamine D2 receptor antagonist (sulpiride), suggesting that THB exhibits an excitatory effect on SNc DA neurons through the block of KATP channels. Collectively, the blockade of neuronal KATP channels by THB in SNc DA neurons is a novel pharmacological mechanism of THB, which may contribute to its neuroprotective effects in PD.
AB - Tetrahydroberberine (THB) exhibits neuroprotective effects but its targets and underlying mechanisms are largely unknown. Emerging evidence indicates that ATP-sensitive potassium (KATP) channels in the substantia nigra pars compacta (SNc) promote Parkinson disease (PD) pathogenesis, thus blocking KATP channels may protect neurons against neuronal degeneration. In the present study, we tested a hypothesis that THB blocks KATP channels in dopaminergic (DA) neurons acutely dissociated from rat SNc. Using perforated patch-clamp recording in current-clamp mode, the functional KATP channels can be opened by persistent perfusion of rotenone, an inhibitor of complex I of the mitochondrial respiratory chain. Bath-application of THB reversibly blocks opened KATP channels in a concentration-dependent manner, which is comparable to a classical KATP channel blocker, Tol. Compared to THB analogs, l-stepholidine (l-SPD) or l-tetrahydropalmatine (l-THP), THB exhibits more profound blockade in KATP channels. In addition, exposure of THB alone to the recorded neuron increases action potential firing, and THB also restores rotenone-induced membrane hyperpolarization in the presence of dopamine D2 receptor antagonist (sulpiride), suggesting that THB exhibits an excitatory effect on SNc DA neurons through the block of KATP channels. Collectively, the blockade of neuronal KATP channels by THB in SNc DA neurons is a novel pharmacological mechanism of THB, which may contribute to its neuroprotective effects in PD.
KW - ATP-sensitive K channel
KW - Dopaminergic neurons
KW - Parch-clamp
KW - Rotenone
KW - Substantia nigra compacta
KW - Tetrahydroberberine
UR - http://www.scopus.com/inward/record.url?scp=77958093745&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77958093745&partnerID=8YFLogxK
U2 - 10.1016/j.neuropharm.2010.08.018
DO - 10.1016/j.neuropharm.2010.08.018
M3 - Article
C2 - 20804776
AN - SCOPUS:77958093745
SN - 0028-3908
VL - 59
SP - 567
EP - 572
JO - Neuropharmacology
JF - Neuropharmacology
IS - 7-8
ER -